The day after a first day of mobilization marked by a new takeover offer, the strike continues on Friday October 18 at Sanofi’s Doliprane production sites, in Lisieux and Compiègne, according to the unions. “The movement continues, there are around fifty of us in front of the site, the determination is still there”declared to Agence France-Presse (AFP) Yohann Nicolas, CGT delegate in Lisieux (Calvados).
Sanofi announced last week that it was negotiating with the American investment fund Clayton Dubilier & Rice (CD&R) in order to potentially sell it 50% of Opella, its subsidiary which houses around a hundred brands of products sold without a prescription around the world, including the Doliprane. On Thursday, the French fund PAI, whose offer had not been accepted last week, increased its bid to buy Opella. A proposal “out of time” who has ” surprised “ the pharmaceutical group.
“The return of PAI to the negotiations changes nothing”estimated Mr. Nicolas, adding: “It’s either the plague or cholera that redeems us. A pension fund remains a pension fund, the fears and concerns are still there. » “Colleagues are worried and suffering, they ask questions about their future without getting answers”concluded the trade unionist.
Read also | Article reserved for our subscribers Sale of Doliprane: PAI tries to relaunch the battle with a new offer
Add to your selections
Production “hugely impacted”
In Compiègne, “the mobilization continues” also, with around forty employees present shortly before 10 a.m. and around a hundred expected at the height of the day, Adil Bensetra, deputy coordinator of the CFDT at Sanofi, told Agence France-Presse (AFP). he assures that there is currently no “no information that allows us to break camp”.
The unions fear a « social coffers » for the 1,700 jobs Opella has on French soil, including 480 in Compiègne (Oise) and 250 in Lisieux. “We are in a battle of numbers, but what interests employees is the maintenance of social achievements, the sustainability of sites and jobs and the possibility of producing in France”et “no one currently gives these guarantees”he regretted.
“Production is hugely impacted”assures the unionist, the mobilized personnel being operators and production technicians essential to the proper functioning of the site.
According to the mayor of Compiègne, Philippe Marini, “the manufacture of Doliprane represents approximately a third of [l’activité] » of this factory.
The president of Sanofi France, Audrey Duval, guaranteed Thursday the “sustainability” jobs, production sites and Doliprane.
Read the editorial of “Le Monde” | The executive in the Doliprane trap
Add to your selections
